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Background: For treatment of the entire cranium using passive scattering proton therapy (PSPT) compensators are
often employed in order to reduce lens and cochlear exposure. We sought to assess the advantages and
consequences of utilizing compensators for the treatment of the whole brain as a component of craniospinal
radiation (CSI) with PSPT. Moreover, we evaluated the potential benefits of spot scanning beam delivery in
comparison to PSPT.
Methods: Planning computed tomography scans for 50 consecutive CSI patients were utilized to generate passive
scattering proton therapy treatment plans with and without Lucite compensators (PSW and PSWO respectively). A
subset of 10 patients was randomly chosen to generate scanning beam treatment plans for comparison. All plans
were generated using an Eclipse treatment planning system and were prescribed to a dose of 36 Gy(RBE), delivered
in 20 fractions, to the whole brain PTV. Plans were normalized to ensure equal whole brain target coverage.
Dosimetric data was compiled and statistical analyses performed using a two-tailed Student’s t-test with Bonferroni
corrections to account for multiple comparisons.
Results: Whole brain target coverage was comparable between all methods. However, cribriform plate coverage
was superior in PSWO plans in comparison to PSW (V95%; 92.9 ± 14 vs. 97.4 ± 5, p < 0.05). As predicted, PSWO plans
had significantly higher lens exposure in comparison to PSW plans (max lens dose Gy(RBE): left; 24.8 ± 0.8 vs. 22.2 ±
0.7, p < 0.05, right; 25.2 ± 0.8 vs. 22.8 ± 0.7, p < 0.05). However, PSW plans demonstrated no significant cochlear
sparing vs. PSWO (mean cochlea dose Gy(RBE): 36.4 ± 0.2 vs. 36.7 ± 0.1, p = NS). Moreover, dose homogeneity was
inferior in PSW plans in comparison to PSWO plans as reflected by significant alterations in both whole brain and
brainstem homogeneity index (HI) and inhomogeneity coefficient (IC). In comparison to both PSPT techniques,
multi-field optimized intensity modulated (MFO-IMPT) spot scanning treatment plans displayed superior sparing of
both lens and cochlea (max lens: 12.5 ± 0.6 and 12.9 ± 0.7 right and left respectively; mean cochlea 28.6 ± 0.5 and
27.4 ± 0.2), although heterogeneity within target volumes was comparable to PSW plans.
Conclusions: For PSPT treatments, the addition of a compensator imparts little clinical advantage. In contrast, the
incorporation of spot scanning technology as a component of CSI treatments, offers additional normal tissue
sparing which is likely of clinical significance.
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Abbreviations: PNET primitive neuroectodermal tumor; ATRT atypical teratoid
rhabdoid tumor.
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For treatment of the entire craniospinal axis, many practi-
tioners consider proton therapy the radiation modality of
choice [1,2]. The physical advantages of proton therapy
for treatment of the spinal target are immediately apparent
when comparisons of proton vs. photon spinal fields are
made [3]. Additionally, benefits for particle therapy are
seen when utilized for treatment of boost fields, such as
sparing of the temporal lobes for patients with posterior
fossa tumors [4].
The majority of proton treatments have been delivered
using PSPT in which brass apertures are utilized to shape
the lateral aspects of a large spread out proton beam [5].
The range of the proton beam, or distal edge, is controlled
through the use of compensators. Compensators function
to adjust the range of the beam across the target in order
to conform the distal edge to the geometry of the target
volume. For treatment of whole brain fields, as a compo-
nent of CSI, compensators are commonly utilized in an at-
tempt to reduce dose to cochleae and lenses [6]. However,
the introduction of material into the beam path may inad-
vertently introduce dose heterogeneity, increase range un-
certainty and in theory increase neutron contamination
[7]. In contrast, with spot scanning proton therapy (SSPT),
a pristine pencil beam is magnetically scanned lateral to
the beam path and different energies are used to achieve
the desired depth distributions [8-11].
In the current study we sought to evaluate the dosi-
metric consequences of utilizing compensators for PSPT
in craniospinal radiation both for organs at risk and dose
homogeneity, in a large cohort of brain tumor patients.
We also sought to evaluate the potential benefits of spot
scanning for such patients.
Methods
Fifty consecutive brain tumor patients treated with cra-
niospinal radiation were included. All patients were con-
sented for and enrolled on prospective studies of proton
therapy approved by the University of Texas MD Anderson
Cancer Center institutional review board. Patient demo-
graphics and tumor histologies are presented in Table 1.
Organs at risk (OARs) including the lens and cochlea along
with target volumes (whole brain and cribriform plate)
were contoured on the simulation computed tomography
scan and each reviewed by a staff radiation oncologist. An
Eclipse treatment planning system (Varian Medical Sys-
tems, Palo Alto, CA) was used for dose calculations and all
plans generated using 2.5 mm slice spacing. For this retro-
spective study, for each patient PSPT had been previously
planned and delivered using a compensator which was
manually edited in order to spare both cochlea and lens
OARs as much as possible, while maintaining target cover-
age. For the present study, clinical PSW plans were copied
and PSWO plans retrospectively generated by deletion ofthe compensator and dose-recalculated with the same
beam line. In order to facilitate comparison, both PSW
and PSWO plans were generated for a prescription dose
of 36 Gy(RBE) in 20 fractions for all patients. For PSPT,
the clinical target volume (CTV) was used for planning
according to standard of practice, as described previously
[12]. Two posterior oblique beams were utilized both for
PSW and PSWO plans, as posteriorly angled beams have
been shown to contribute to sparing of the lens while
allowing adequate coverage of the cribriform plate [13].
A subset of 10 patients was subsequently chosen for plan-
ning with multi-field optimized intensity modulated proton
therapy (MFO-IMPT) [14]. Because a robust optimization
technique [15] is not currently available in our clinical
treatment planning system, for IMPT planning, a planning
target volume (PTV) was used for optimization, which in-
cluded both setup and range uncertainties, in line with our
current clinical practice. For cochleae, the planning organ
at risk volume (PRV) was defined as a 5-mm expansion
from the cochleae. The optimization volume was then de-
fined as PTV minus PRV for cochleae. The spot spacing
was 7 to 9 mm. The lateral field margin in the beams-eye-
view was set equal to 8 mm, i.e., one spot was allowed to be
outside the optimization volume [16]. A 1-cm width, dose-
limiting ring peripheral to optimization volume was used to
shape the dose gradient exterior to target, and to eliminate
boundary hot spots. Lenses and cochleae were nominally
constrained to 10 and 28 Gy, respectively. The optimization
included the cribriform plate as an additional target volume
to facilitate prescription dose coverage. A 6.7 cm thick
range shifter was placed at the end of the nozzle to enable
coverage of shallow target volume regions. The air gap
was kept as small as possible to minimize the spot size
and yet large enough to have the sufficient clearance for
treatment delivery.
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simetrists and medical physicists experienced with each
modality. Qualitative and quantitative evaluations were
conducted for each treatment plan generated. Dosimetric
data were compiled including mean cochlear dose (left and
right), maximum lens dose (left and right), maximum
brainstem dose etc. To evaluate target coverage, V95% was
evaluated for the whole brain as well as cribriform plate.
To evaluate dose homogeneity we calculated both the
homogeneity index (HI =D5/D95) as well as the inhomo-
geneity coefficient (IC =D5-D95/Dmean) [17,18]. For each
index a lower value indicates superior dose homogeneity.
Statistical significance was determined by a two-tailed t-
test with Bonferroni corrections employed to account for
multiple comparisons.
Results
For the patient cohort investigated, the mean age at si-
mulation was 18 years with a range of 2 to 65 years.
Thirty-five patients were ≤18 years of age. Sixty percent of
patients were male (Table 1). Forty six percent of patients
were treated for medulloblastoma. The second most com-
mon indication was germ cell tumor followed by less com-
mon histologies (Table 1).
For both PSW and PSWO, whole brain target coverage
was comparable (Table 2). However, the V95% for the crib-
riform plate was significantly higher for PSWO plans, an
anatomical area which, if inadequately covered, may be as-
sociated with an increased risk of disease recurrence [19].
We next compared PSW and PSWO treatment plans in
terms of OAR exposure. As expected, without the capacity
for distal blocking offered by the addition of a compensa-
tor, PSWO plans had significantly higher maximum lens
doses (Figure 1A). However, the addition of a compensator,
offered no significant cochlear sparing (Figure 1B). Further-
more, qualitative review of plans suggested additional dose
heterogeneity within the brainstem for PSW (Figure 1C).
In order to quantitatively compare plan heterogeneity,
we compared the homogeneity index (HI) and inhomo-
geneity coefficients (IC) for each plan type both for
whole brain and brainstem. In comparison to plans gen-
erated with a compensator, PSWO plans were signifi-
cantly more homogenous (Table 3). This was true bothTable 2 Comparison of target volume coverage
Index PSW (Gy(RBE) or %) PSWO (Gy(RBE) or %)
V95% - whole brain 98.5 ± 2.7 98.5 ± 2.8
D95 - whole brain 36.2 ± 0.9 36.1 ± 0.5
V95% - cribriform plate 92.9 ± 14 97.4 ± 5*
Abbreviations: PSW passive scatter with compensator; PSWO passive scatter
without compensator; V95% = percentage of the target volume that receives
at least 95% of the prescribed dose; D95 = dose volume histogram (DVH) curve
dose representing 95% of volume of the target. Data presented as mean ±
standard deviation; *significant vs. PSW (p < 0.05), Student’s t-test with Bonferroni
correction for multiple comparisons.for the whole brain as well as for the brainstem where the
magnitude of change was greater. This is presumably due
to the close proximity of the brainstem and cochlea, where
steep compensator edits would be expected to degrade
plan homogeneity (Figure 1C).
Based on the lack of cochlear sparing observed with both
PSPT techniques. We next investigated the potential utility
of spot scanning. Multi-field optimized IMPT plans,
encompassing the cranium and cervical spine, were created
utilizing one posterior (PA) and two anterior-oblique (AO)
beams (left and right), all sharing a common isocenter.
Employing a PA beam reduced thyroid dose and enabled
coverage of the spine target inferior to the shoulder with-
out reimaging, thus reducing the required number of iso-
centers inferiorly along the spine for most patients. For
AO beams, the nominal beam angle was 75 degrees off the
medial plane. This placement provided a beams eye view
of much of the brain target, unencumbered by the dose-
limiting cochlea. For the majority of plans, AO beams also
included a 15-degree superior couch rotation, facilitating
dose reduction to the eyes and lenses, while maintaining
cribriform plate coverage. AO beams further ensured that
target coverage near the dose sensitive lenses was not prin-
cipally from the distal portion of the PA proton beam.
IMPT plans displayed target coverage comparable to
that of PSW plans (whole brain; V95% 99.8 ± 0.15, D95
36.5 ± 0.2 and cribriform plate; V95% 96.9 ± 2.4, D95
36.7 ± 0.3). In comparison to both PSW and PSWO
techniques, IMPT plans demonstrated superior OAR
sparing (Table 4, Figure 2A). However, utilizing the cur-
rently available optimization techniques, heterogeneity
within the brain target was inferior compared to PSWO
plans (whole brain; HI 1.053 ± 0.003, p < 0.05, Figure 2B)
but similar when the brainstem was evaluated separately
(brainstem; HI 1.04 ± 0.008, p = NS).
Discussion
Unnecessary radiation exposure to normal tissues, particu-
larly in pediatric patients, is associated with increased risks
of long-term adverse effects [20,21]. Lens and cochlear ex-
posure in particular are associated with cataract formation
and decreased hearing acuity respectively [22,23]. The
current study, conducted in a large number of patients,
supports the results of Jin et al. who also found that the
addition of a compensator to PSPT increased heterogen-
eity [6]. This study adds additional information on the
sparing, or lack thereof, of OARs as well as exploring po-
tential benefits of IMPT. We found that the addition of
compensators to whole brain treatments, as a component
of CSI delivered with PSPT, offered modest lens sparing
and little cochlear sparing at the expense of added hetero-
geneity. Moreover, cribriform plate coverage was superior
in PSWO plans compared to PSW. Whole brain treatment
plans generated using discrete spot scanning IMPT,
Figure 1 Comparison of PSPT plans with and without compensators. (A) Box-and-whisker plot of maximum lens dose, right and left, for
PSW and PSWO plans. Vertical bars represent range and central bar median. (B) Box-and-whisker plot of mean cochlear dose, right and left, for
PSW and PSWO plans. (C) Representative axial computed tomographic plans with and without compensators. Axial sections, at the level of the
cochlea (highlighted in orange), demonstrate dose heterogeneity introduced by the compensator edge, extending through the brainstem. Yellow
arrows depict the beam angles utilized. *significant vs. PSW, (p < 0.05), Student’s t-test with Bonferroni correction for multiple comparisons.
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ing of lens and cochlea in comparison to either PSPT tech-
nique. However, dose heterogeneity was increased in IMPT
plans.
Sensorineural hearing loss is common following brain
irradiation. Especially in pediatric patients, diminished
hearing may predispose to impaired communication skillsTable 3 Dose heterogeneity
Index PSW (Gy(RBE) or %) PSWO (Gy(RBE) or %)
HI - whole brain 1.038 ± 0.01 1.031 ± 0.01*
IC - whole brain 0.036 ± 0.01 0.03 ± 0.01*
HI - brainstem 1.064 ± 0.06 1.028 ± 0.05*
IC - brainstem 0.06 ± 0.05 0.026 ± 0.04*
Abbreviations: PSW passive scatter with compensator; PSWO passive scatter
without compensator; HI (homogeneity index) = D5/D95; IC (inhomogeneity
coefficient) = D5% - D95%/Dmean; Data presented as mean ± standard
deviation. *significant vs. PSW (p < 0.05), Student’s t-test with Bonferroni
correction for multiple comparisons.resulting in diminished cognitive development and ultim-
ately inferior quality of life. For children, treated with radi-
ation alone, it has been suggested that cochlear doses be
limited to less than 35 Gy in order to reduce the risk of
ototoxicity [23]. A similar dose response is likely present
in adult patients [24]. The addition of platinum based
chemotherapy, as in the treatment of medulloblastoma, is
expected to further increase the risk of cochlear damage
[25,26]. In comparison to patients treated with photon
techniques, including IMRT, published studies have dem-
onstrated that patients treated to the craniospinal axis
with PSPT have favorable hearing outcomes with low rates
of high grade hearing loss [27-29]. These results highlight
the clinical benefits of proton therapy and are likely due to
cochlear sparing during the boost portion of therapy
which is superior to photon techniques [2]. However,
nearly 50% of patients did experience low-grade ototox-
icity after PSPT based CSI, suggesting further room for
improvement [27]. Thus, our finding that IMPT reduced
Table 4 Organs at risk
Index PSW (Gy(RBE)) PSWO (Gy(RBE)) IMPT (Gy(RBE))
Left cochlea (mean) 36.4 ± 1.3 36.7 ± 1.0 28.6 ± 3.3†
Right cochlea (mean) 36.4 ± 1.4 36.7 ± 0.9 27.4 ± 1.5†
Left lens (max) 22.2 ± 5.5 24.8 ± 6.1* 12.5 ± 4.0†
Right lens (max) 22.8 ± 5.2 25.2 ± 5.9* 12.9 ± 5.0†
Brainstem (max) 39.3 ± 2.0 38.8 ± 2.0* 38.4 ± 0.5
Abbreviations: PSW passive scatter with compensator; PSWO passive scatter without compensator; IMPT intensity modulated proton therapy; Data presented as
mean ± standard deviation; *significant vs. PSW, †significant vs. PSW or PWO, (p < 0.05), Student’s t-test with Bonferroni correction for multiple comparisons.
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treatment may have clinical significance.
In contrast to therapy-induced ototoxicity, which is
largely irreversible, radiation-induced cataracts may be ad-
dressed surgically. However, clinical outcomes following
lens replacement may be defined by the health of other
remaining ocular structures [30]. Similar to otic structures,
the exact dose response of the lens is complicated and in-
fluenced by both patient and radiation related factors such
as fraction size and dose rate among others [31-33]. Re-
gardless, additional sparing of both lens and other optic
structures maybe expected to potentially avoid unnecessary
surgical interventions. While we found that lens doses with
PSWO plans were significantly higher than PSW plans.
IMPT plans demonstrated the best lens sparing, while
maintaining cribriform plate coverage. Based on studies of
lens sparing during fractionated radiation therapy, the add-
itional sparing offered by IMPT would be expected to re-
duce the incidence of cataract formation [34].
The current study did not include a comparison of pho-
ton based intensity modulated radiation therapy (IMRT).
However, previous work has shown that IMRT plans have
significantly higher dose heterogeneity in comparison to
PSPT plans. However, of note the reported HI values areFigure 2 Representative axial sections of a multi-field intensity modu
cochlear sparing (depicted in orange and blue color wash, right and left re
arrow) while maintaining coverage of the cribriform plate (opaque magentsimilar to those we recorded in MFO-IMPT planning [35].
Regardless, given the potential setup uncertainties which
would be introduced by patient transfer between photon
and proton treatment rooms, mixed modality CSI (IMRT
brain and proton spine) is not clinically favored.
In our current clinical practice, we utilize PSPT without
the routine use of compensators for treatment of the cra-
niospinal axis. Many new proton centers will have the cap-
acity for spot scanning therapy and some will exclusively
employ this modality. The safe delivery of radiation to the
entire craniospinal axis is technically challenging regardless
of the radiation technique. While published work suggests
that CSI delivered with PSPT is safe and efficacious [1,36],
additional in silico and clinical studies will be necessary in
order to implement CSI treatment using scanned beams.
This is highlighted by the present study where scanned
beam plans were found to be more inhomogeneous than
PSWO plans. Further study including the adaptation of
alternate optimizers, novel junctioning techniques etc.,
is expected to further improve dosimetric outcomes and
to make CSI delivered with spot scanning a clinical real-
ity. It is hoped that this will translate into further im-
provements in outcomes, including reduction of lens
and cochlear toxicities.lated proton therapy plan. Images demonstrate the capacity for (A)
spectively) as well as (B) lens sparing (left lens highlighted by blue
a). Yellow arrows depict the beam angles utilized.
Dinh et al. Radiation Oncology 2013, 8:289 Page 6 of 7
http://www.ro-journal.com/content/8/1/289Abbreviations
AO: Anterior-oblique; ATRT: Atypical teratoid rhabdoid tumor; CSI: Craniospinal
radiation; CTV: Clinical target volume; DVH: Dose volume histogram;
HI: Homogeneity index; IC: Inhomogeneity coefficient; MFO-IMPT: Multi-field
optimized intensity modulated; OARs: Organs at risk; PNET: Primitive
neuroectodermal tumor; PRV: Planning organ at risk volume; PSPT: Passive
scattering proton therapy; PSW: Passive scattering proton therapy with
compensator; PSWO: Passive scattering proton therapy without compensator;
PTV: Planning target volume; SSPT: Spot scanning proton therapy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JD compiled and analyzed dosimetric data and drafted the manuscript. JS
developed IMPT methodologies and treatment plans, compiled and analyzed
dosimetric data and drafted the manuscript. RHG developed PSPT plans and
compiled dosimetric data. NS conceived of the concept of the study and
oversaw its completion. XRZ participated in the development of IMPT
methodology and treatment planning. SR compiled and analyzed dosimetric
data. AM conceived of the concept study and participated in its completion.
DRG conceived of the study concept, participated in all aspects of its design
and coordination and helped to draft the manuscript. All authors read and
approved the final manuscript.
Author details
1Departments of Radiation Oncology, The University of Texas M.D. Anderson
Cancer Center, 1515 Holcombe Blvd., Unit 1150, Houston, TX 77030, USA.
2Departments of Radiation Physics, Division of Radiation Oncology, The
University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Received: 9 September 2013 Accepted: 8 November 2013
Published: 17 December 2013
References
1. Brown AP, Barney CL, Grosshans DR, McAleer MF, de Groot JF, Puduvalli VK,
Tucker SL, Crawford CN, Khan M, Khatua S: Proton beam craniospinal
irradiation reduces acute toxicity for adults with medulloblastoma. Int J
Radiat Oncol Biol Phys 2013, 86:277–284. Doi: 210.1016/j.
ijrobp.2013.1001.1014.
2. St Clair WH, Adams JA, Bues M, Fullerton BC, La Shell S, Kooy HM, Loeffler
JS, Tarbell NJ: Advantage of protons compared to conventional X-ray or
IMRT in the treatment of a pediatric patient with medulloblastoma. Int J
Radiat Oncol Biol Phys 2004, 58:727–734.
3. Amsbaugh MJ, Grosshans DR, McAleer MF, Zhu R, Wages C, Crawford CN,
Palmer M, De Gracia B, Woo S, Mahajan A: Proton therapy for spinal
ependymomas: planning, acute toxicities, and preliminary outcomes.
Int J Radiat Oncol Biol Phys 2012, 83:1419–1424. Doi: 1410.1016/j.
ijrobp.2011.1410.1034.
4. Lin R, Hug EB, Schaefer RA, Miller DW, Slater JM, Slater JD: Conformal
proton radiation therapy of the posterior fossa: a study comparing
protons with three-dimensional planned photons in limiting dose to
auditory structures. Int J Radiat Oncol Biol Phys 2000, 48:1219–1226.
5. DeLaney TF: Proton therapy in the clinic. Front Radiat Ther Oncol 2011,
43:465–485.
6. Jin H, Hsi W, Yeung D, Li Z, Mendenhall NP, Marcus RB Jr: Dosimetric
characterization of whole brain radiotherapy of pediatric patients using
modulated proton beams. J Appl Clin Med Phys 2011, 12:3308.
7. Hall EJ: Intensity-modulated radiation therapy, protons, and the risk of
second cancers. Int J Radiat Oncol Biol Phys 2006, 65:1–7.
8. Delaney TF, Kooy HM: Proton and Charged Particle Radiotherapy.
Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins; 2008.
9. Haberer T, Becher W, Schardt D, Kraft G: Magnetic scanning system for
heavy ion therapy. Nucl Instrum Methods Phys Res A 1993, 330:296–305.
10. ICRU: Prescribing, Recording, and Reporting Proton-Beam Therapy. Washington
DC: International Commission on Radiation Units and Measurements; 2007.
11. Pedroni E, Bacher R, Blattmann H, Bohringer T, Coray A, Lomax A, Lin S,
Munkel G, Scheib S, Schneider U, et al: The 200-MeV proton therapy
project at the Paul Scherrer Institute: conceptual design and practical
realization. Med Phys 1995, 22:37–53.12. Giebeler A, Newhauser WD, Amos RA, Mahajan A, Homann K, Howell RM:
Standardized treatment planning methodology for passively scattered
proton craniospinal irradiation. Radiat Oncol 2013, 8:32.
13. Cochran DM, Yock TI, Adams JA, Tarbell NJ: Radiation dose to the lens during
craniospinal irradiation-an improvement in proton radiotherapy technique.
Int J Radiat Oncol Biol Phys 2008, 70:1336–1342. Epub 2007 Oct 1329.
14. Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, Cox JD, Chang JY:
Intensity-modulated proton therapy reduces the dose to normal tissue
compared with intensity-modulated radiation therapy or passive
scattering proton therapy and enables individualized radical
radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual
clinical study. Int J Radiat Oncol Biol Phys 2010, 77:357–366. Doi: 310.1016/j.
ijrobp.2009.1004.1028. Epub 2009 Aug 1015.
15. Liu W, Li Y, Li X, Cao W, Zhang X: Influence of robust optimization in
intensity-modulated proton therapy with different dose delivery
techniques. Med Phys 2012, 39:3089–3101.
16. Zhu XR, Sahoo N, Zhang X, Robertson D, Li H, Choi S, Lee AK, Gillin MT:
Intensity modulated proton therapy treatment planning using single-field
optimization: the impact of monitor unit constraints on plan quality.
Med Phys 2010, 37:1210–1219.
17. Kataria T, Sharma K, Subramani V, Karrthick KP, Bisht SS: Homogeneity
index: an objective tool for assessment of conformal radiation
treatments. J Med Phys 2012, 37:207–213. Doi: 210.4103/0971-6203.103606.
18. Boehling NS, Grosshans DR, Bluett JB, Palmer MT, Song X, Amos RA, Sahoo
N, Meyer JJ, Mahajan A, Woo SY: Dosimetric comparison of three-
dimensional conformal proton radiotherapy, intensity-modulated proton
therapy, and intensity-modulated radiotherapy for treatment of pediatric
craniopharyngiomas. Int J Radiat Oncol Biol Phys 2011, 27:27.
19. Halperin EC: Impact of radiation technique upon the outcome of treatment
for medulloblastoma. Int J Radiat Oncol Biol Phys 1996, 36:233–239.
20. Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS,
Green DM, Hammond S, Meadows AT, Mertens AC: The Childhood Cancer
Survivor Study: a National Cancer Institute-supported resource for
outcome and intervention research. J Clin Oncol 2009, 27:2308–2318.
Epub 2009 Apr 2313.
21. Ellenberg L, Liu Q, Gioia G, Yasui Y, Packer RJ, Mertens A, Donaldson SS,
Stovall M, Kadan-Lottick N, Armstrong G, et al: Neurocognitive status in
long-term survivors of childhood CNS malignancies: a report from the
Childhood Cancer Survivor Study. Neuropsychology 2009, 23:705–717.
22. Bhandare N, Jackson A, Eisbruch A, Pan CC, Flickinger JC, Antonelli P,
Mendenhall WM: Radiation therapy and hearing loss. Int J Radiat Oncol
Biol Phys 2010, 76:S50–57. Doi: 10.1016/j.ijrobp.2009.1004.1096.
23. Hua C, Bass JK, Khan R, Kun LE, Merchant TE: Hearing loss after
radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J
Radiat Oncol Biol Phys 2008, 72:892–899. Doi: 810.1016/j.
ijrobp.2008.1001.1050. Epub 2008 Apr 1018.
24. Honore HB, Bentzen SM, Moller K, Grau C: Sensori-neural hearing loss after
radiotherapy for nasopharyngeal carcinoma: individualized risk
estimation. Radiother Oncol 2002, 65:9–16.
25. Knight KR, Kraemer DF, Neuwelt EA: Ototoxicity in children receiving
platinum chemotherapy: underestimating a commonly occurring toxicity
that may influence academic and social development. J Clin Oncol 2005,
23:8588–8596.
26. Kolinsky DC, Hayashi SS, Karzon R, Mao J, Hayashi RJ: Late onset hearing
loss: a significant complication of cancer survivors treated with Cisplatin
containing chemotherapy regimens. J Pediatr Hematol Oncol 2010,
32:119–123. Doi: 110.1097/MPH.1090b1013e3181cb8593.
27. Moeller BJ, Chintagumpala M, Philip JJ, Grosshans DR, McAleer MF, Woo SY,
Gidley PW, Vats TS, Mahajan A: Low early ototoxicity rates for pediatric
medulloblastoma patients treated with proton radiotherapy. Radiat Oncol
2011, 6:58.
28. Paulino AC, Lobo M, Teh BS, Okcu MF, South M, Butler EB, Su J,
Chintagumpala M: Ototoxicity after intensity-modulated radiation therapy
and cisplatin-based chemotherapy in children with medulloblastoma.
Int J Radiat Oncol Biol Phys 2010, 78:1445–1450. Doi: 1410.1016/j.
ijrobp.2009.1409.1031. Epub 2010 Mar 1416.
29. Polkinghorn WR, Dunkel IJ, Souweidane MM, Khakoo Y, Lyden DC,
Gilheeney SW, Becher OJ, Budnick AS, Wolden SL: Disease control and
ototoxicity using intensity-modulated radiation therapy tumor-bed boost
for medulloblastoma. Int J Radiat Oncol Biol Phys 2011, 81:e15–20.
Doi: 10.1016/j.ijrobp.2010.1011.1081. Epub 2011 Apr 1012.
Dinh et al. Radiation Oncology 2013, 8:289 Page 7 of 7
http://www.ro-journal.com/content/8/1/28930. Osman IM, Abouzeid H, Balmer A, Gaillard MC, Othenin-Girard P, Pica A,
Moeckli R, Schorderet DF, Munier FL: Modern cataract surgery for
radiation-induced cataracts in retinoblastoma. Br J Ophthalmol 2011,
95:227–230. Doi: 210.1136/bjo.2009.173401. Epub 172010 Jun 173424.
31. Merriam GR Jr, Focht EF, Parsons RW: The relative radiosensitivity of the
young and the adult lens. Radiology 1969, 92:1114.
32. Britten MJ, Halnan KE, Meredith WJ: Radiation cataract–new evidence on
radiation dosage to the lens. Br J Radiol 1966, 39:612–617.
33. Deeg HJ, Flournoy N, Sullivan KM, Sheehan K, Buckner CD, Sanders JE, Storb R,
Witherspoon RP, Thomas ED: Cataracts after total body irradiation and
marrow transplantation: a sparing effect of dose fractionation. Int J Radiat
Oncol Biol Phys 1984, 10:957–964.
34. Henk JM, Whitelocke RA, Warrington AP, Bessell EM: Radiation dose to the
lens and cataract formation. Int J Radiat Oncol Biol Phys 1993, 25:815–820.
35. Howell RM, Giebeler A, Koontz-Raisig W, Mahajan A, Etzel CJ, D’Amelio AM Jr,
Homann KL, Newhauser WD: Comparison of therapeutic dosimetric data
from passively scattered proton and photon craniospinal irradiations for
medulloblastoma. Radiat Oncol 2012, 7:116. 10.1186/1748-1717X-1187-1116.
36. Jimenez RB, Sethi R, Depauw N, Pulsifer MB, Adams J, McBride SM, Ebb D,
Fullerton BC, Tarbell NJ, Yock TI, Macdonald SM: Proton radiation therapy
for pediatric medulloblastoma and supratentorial primitive
neuroectodermal tumors: outcomes for very young children treated with
upfront chemotherapy. Int J Radiat Oncol Biol Phys 2013, 21:017.
doi:10.1186/1748-717X-8-289
Cite this article as: Dinh et al.: Comparison of proton therapy
techniques for treatment of the whole brain as a component of
craniospinal radiation. Radiation Oncology 2013 8:289.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
